A
Atul R. Mahableshwarkar
Researcher at Takeda Pharmaceutical Company
Publications - 40
Citations - 1470
Atul R. Mahableshwarkar is an academic researcher from Takeda Pharmaceutical Company. The author has contributed to research in topics: Vortioxetine & Placebo. The author has an hindex of 17, co-authored 33 publications receiving 1230 citations. Previous affiliations of Atul R. Mahableshwarkar include Harvard University.
Papers
More filters
Journal ArticleDOI
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
TL;DR: In this study of MDD adults who self-reported cognitive dysfunction, vortioxetine significantly improved cognitive function, depression, and functionality and was generally well tolerated.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder.
TL;DR: After 8 weeks of treatment with Lu AA21004 10 mg, there was a significant reduction in HDRS-24 total score compared with placebo in adults with major depressive disorder, and the drug was well tolerated in this study.
Journal ArticleDOI
A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults
TL;DR: An aggregated study-level meta-analysis of vortioxetine (5-20mg/day) in adults with MDD supports the efficacy demonstrated in the individual studies, with treatment effect increasing with dose.
Journal ArticleDOI
A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder
TL;DR: In this study of adults with MDD treated for 8 weeks with vortioxetine 2.5 mg or 5mg per day, reductions in depression symptoms were not statistically significant compared with placebo and both doses of vortoxetine were well tolerated.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder
TL;DR: 5 mg vortioxetine did not differ significantly from placebo in reducing depression symptoms after 6 wk of treatment in adults with MDD in an out-patient setting.